Novel and emerging treatments for major depression

Steven Marwaha; Edward Palmer; Trisha Suppes; Emily Cons; Allan H. Young; Rachel Upthegrove

doi:10.1016/S0140-6736(22)02080-3

Novel and emerging treatments for major depression

Steven Marwaha, Edward Palmer, Trisha Suppes, Emily Cons, Allan H. Young, Rachel Upthegrove^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

272 Citations (Scopus)

Abstract

Depression is common, costly, debilitating, and associated with increased risk of suicide. It is one of the leading global public health problems. Although existing available pharmacological treatments can be effective, their onset of action can take up to 6 weeks, side-effects are common, and recovery can require treatment with multiple different agents. Although psychosocial interventions might also be recommended, more effective treatments than those currently available are needed for people with moderate or severe depression. In the past 10 years, treatment trials have developed and tested many new targeted interventions. In this Review, we assess novel and emerging biological treatments for major depressive disorder, evaluate their putative brain and body mechanisms, and highlight how close each might be to clinical use.

Original language	English
Pages (from-to)	141-153
Number of pages	13
Journal	The Lancet
Volume	401
Issue number	10371
DOIs	https://doi.org/10.1016/S0140-6736(22)02080-3
Publication status	Published - 14 Jan 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0140-6736(22)02080-3

Cite this

@article{d51be05871fe41b8888b1d67a00b04fa,

title = "Novel and emerging treatments for major depression",

abstract = "Depression is common, costly, debilitating, and associated with increased risk of suicide. It is one of the leading global public health problems. Although existing available pharmacological treatments can be effective, their onset of action can take up to 6 weeks, side-effects are common, and recovery can require treatment with multiple different agents. Although psychosocial interventions might also be recommended, more effective treatments than those currently available are needed for people with moderate or severe depression. In the past 10 years, treatment trials have developed and tested many new targeted interventions. In this Review, we assess novel and emerging biological treatments for major depressive disorder, evaluate their putative brain and body mechanisms, and highlight how close each might be to clinical use.",

author = "Steven Marwaha and Edward Palmer and Trisha Suppes and Emily Cons and Young, {Allan H.} and Rachel Upthegrove",

note = "Funding Information: We thank Connor Dunleavy (University of Birmingham, UK) for assistance with the figures in this Review. Publisher Copyright: {\textcopyright} 2023 Elsevier Ltd",

year = "2023",

month = jan,

day = "14",

doi = "10.1016/S0140-6736(22)02080-3",

language = "English",

volume = "401",

pages = "141--153",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier",

number = "10371",

}

TY - JOUR

T1 - Novel and emerging treatments for major depression

AU - Marwaha, Steven

AU - Palmer, Edward

AU - Suppes, Trisha

AU - Cons, Emily

AU - Young, Allan H.

AU - Upthegrove, Rachel

PY - 2023/1/14

Y1 - 2023/1/14

N2 - Depression is common, costly, debilitating, and associated with increased risk of suicide. It is one of the leading global public health problems. Although existing available pharmacological treatments can be effective, their onset of action can take up to 6 weeks, side-effects are common, and recovery can require treatment with multiple different agents. Although psychosocial interventions might also be recommended, more effective treatments than those currently available are needed for people with moderate or severe depression. In the past 10 years, treatment trials have developed and tested many new targeted interventions. In this Review, we assess novel and emerging biological treatments for major depressive disorder, evaluate their putative brain and body mechanisms, and highlight how close each might be to clinical use.

AB - Depression is common, costly, debilitating, and associated with increased risk of suicide. It is one of the leading global public health problems. Although existing available pharmacological treatments can be effective, their onset of action can take up to 6 weeks, side-effects are common, and recovery can require treatment with multiple different agents. Although psychosocial interventions might also be recommended, more effective treatments than those currently available are needed for people with moderate or severe depression. In the past 10 years, treatment trials have developed and tested many new targeted interventions. In this Review, we assess novel and emerging biological treatments for major depressive disorder, evaluate their putative brain and body mechanisms, and highlight how close each might be to clinical use.

UR - http://www.scopus.com/inward/record.url?scp=85146230128&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(22)02080-3

DO - 10.1016/S0140-6736(22)02080-3

M3 - Review article

C2 - 36535295

AN - SCOPUS:85146230128

SN - 0140-6736

VL - 401

SP - 141

EP - 153

JO - The Lancet

JF - The Lancet

IS - 10371

ER -

Novel and emerging treatments for major depression

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this